Limited knowledge on progestogen-only contraception and risk of venous thromboembolism

References

• Winkler UH. Blood coagulation and oral contraceptives. A critical review. Contraception 1998; 57: 203–9
   PubMed Web of Science ®Google Scholar
• Winkler UH, Holscher T, Schulte H, Zierleyn JP, Collet W, Schindler AE. Ethinylestradiol 20 versus 30 micrograms combined with 150 micrograms desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system. Gynecol Endocrinol 1996; 10: 265–71
   PubMed Web of Science ®Google Scholar
• Mammen EF. Pathogenesis of venous thrombosis. Chest 1992; 102: 640S–4
   PubMed Web of Science ®Google Scholar
• Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996; 24: 1–19
   PubMed Web of Science ®Google Scholar
• van Rooijen M, Silveira A, Thomassen S, Hansson LO, Rosing J, Hamsten A, et al. Rapid activation of haemostasis after hormonal emergency contraception. Thromb Haemost 2007; 97: 15–20
   PubMed Web of Science ®Google Scholar
• Schindler AE. Differential effects of progestins on hemostasis. Maturitas 2003; 46: S31–7
   PubMed Web of Science ®Google Scholar
• Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol. 2006; 6: 50
   PubMed Web of Science ®Google Scholar
• Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996; 54: 5–13
   PubMed Web of Science ®Google Scholar
• World Health Organization CSoCDaSHC. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception. 1998;57:315–24.
   PubMed Web of Science ®Google Scholar
• Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4: 67–73
   PubMedGoogle Scholar
• Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354: 1610–1
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187–96
   PubMed Web of Science ®Google Scholar
• Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, Thalabard JC. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004; 70: 437–41
   PubMed Web of Science ®Google Scholar
• Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 1999; 60: 1–8
   PubMed Web of Science ®Google Scholar
• Hirani V, Zaninotto P, Primatesta P. Generalised and abdominal obesity and risk of diabetes, hypertension and hypertension-diabetes co-morbidity in England. Public Health Nutr. 2008; 11: 521–7
   PubMed Web of Science ®Google Scholar
• Doyle J, Stern L, Hagan M, Hao J, Gricar J. Advances in contraception: IUDs from a managed care perspective. J Womens Health (Larchmt) 2008; 17: 987–92
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527–35
   PubMed Web of Science ®Google Scholar
• Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 2001; 104: 2826–31
   PubMed Web of Science ®Google Scholar
• Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 680–90
   PubMed Web of Science ®Google Scholar
• Whigham KA, Howie PW, Mack A, Prentice CR. The effect of an injectable progestogen contraceptive on blood coagulation and fibrinolysis. Br J Obstet Gynaecol 1979; 86: 806–9
   PubMedGoogle Scholar
• Blomback M, Landgren BM, Stiernholm Y, Andersson O. The effect of progesterone on the haemostatic mechanism. Thromb Haemost 1997; 77: 105–8
   PubMed Web of Science ®Google Scholar
• Singh K, Viegas OA, Koh SC, Ratnam SS. Effect of long-term use of Norplant implants on haemostatic function. Contraception 1992; 45: 203–19
   PubMed Web of Science ®Google Scholar
• Lira P, Rivera L, Diaz S, Croxatto HB. Study of blood coagulation in women treated with megestrol acetate implants. Contraception 1975; 12: 639–44
   PubMed Web of Science ®Google Scholar
• World Health Organization CSoCDaSHC. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 1995;346:1575–82.
   PubMed Web of Science ®Google Scholar